BESTSELLER

Stem Cell Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Stem Cell Market is Segmented by Product Type (Adult Stem Cell, Human Embryonic Cell, Pluripotent Stem Cell, and Other Product Types), Application (Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Injuries and Wounds, Cardiovascular Disorders, and Other Applications), Treatment Type (Allogeneic Stem Cell Therapy, Auto logic Stem Cell Therapy, and Syngeneic Stem Cell Therapy) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD billion) for the above segments.

Market Snapshot

Stem Cell Market Overview
Study Period: 2018-2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10.24 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The stem cell market was valued at USD 14.7 billion in 2020, and it is expected to reach approximately USD 26.40 billion in 2026, registering a CAGR of nearly 10.24% during the forecast period, 2021-2026. The growth of the market is attributed to the rising number of clinical trials and the growing adoption of stem cell therapies globally. In the context of COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on effective and rapid technologies for the fast diagnosis of COVID-19. According to a 2020 research article published in the scientific journal Aging and Disease (2020), mesenchymal stem cells are a safe and effective approach to the treatment of COVID-19. At least 10 projects have been registered in the official international registry for clinical trials, implicating the use of mesenchymal stem cells to patients with coronavirus pneumonia. However, it is still at an initial stage of study in relation to the market studied.

Stem cells are majorly used in regenerative medicine, especially in the field of dermatology. However, oncology is expected to grow at the highest rate due to a large number of pipeline products present for the treatment of tumors or cancers. With the increase in the number of regenerative medicine centers, the stem cell market is also expected to increase in the future.

One of the richest sources of stem cells is the umbilical cord, which possesses unique qualities and has greater advantages over embryonic stem cells or adult stem cells. There are an increasing number of stem cell banks, which collaborate with hospitals and increase awareness about the storage of cord blood units in families, particularly in the emerging markets. The support is increasing with the rising number of medical communities and government initiatives active in promoting the use of stem cells for the treatment of more than 100 diseases. Currently, there is an increase in the number of clinical trials for testing future treatment possibilities of cord blood. Over 200 National Institutes of Health (NIH)-funded clinical trials with cord blood are currently being conducted in the United States alone.

Scope of the Report

As per the scope of the report, stem cells are biological cells that can differentiate into other types of cells. Additionally, various types of stem cells are used for therapeutic purposes. With multiple applications at the clinical stage for various diseases, these are being explored extensively by a large number of biopharmaceutical companies in recent times. The market is segmented by product type (adult stem cell, human embryonic cell, pluripotent stem cell, and other product types), application (neurological disorders, orthopedic treatments, oncology disorders, injuries and wounds, cardiovascular disorders, and other applications), treatment type (allogeneic stem cell therapy, auto logic stem cell therapy, and syngeneic stem cell therapy) and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD billion) for the above segments.

By Product Type
Adult Stem Cell
Human Embryonic Cell
Pluripotent Stem Cell
Other Product Types
By Application
Neurological Disorders
Orthopedic Treatments
Oncology Disorders
Injuries and Wounds
Cardiovascular Disorders
Other Applications
By Treatment Type
Allogeneic Stem Cell Therapy
Autologic Stem Cell Therapy
Syngeneic Stem Cell Therapy
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Oncology Disorders Segment is Expected to Exhibit the Fastest Growth Rate Over the Forecast Period

The global cancer burden has been increasing, and thus, cancer therapies must be modified according to regional and national priorities. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world. According to the World Health Organization (WHO), cancer is the second-leading cause of death across the world, with an estimated number of 9.6 million deaths in 2018, accounting for nearly one in six deaths.

Bone marrow transplant or stem cell transplant is a treatment for some types of cancer, like leukemia, multiple myeloma, neuroblastoma, or some types of lymphoma. For cancer treatments, both autologous and allogeneic stem cell transplants are done. Autologous transplants are preferred in the case of leukemias, lymphomas, multiple myeloma, testicular cancer, and neuroblastoma.

The major disadvantage associated with autologous stem cell transplants in cancer therapy is that cancer cells sometimes also get collected, along with stem cells, which may further put it back into the body during the therapy.

In case of allogeneic stem cell transplants, the donor can often be asked to donate more stem cells or even white blood cells, as per the requirement, and stem cells from healthy donors are free of cancer cells. However, the transplanted donor stem cells could die or be destroyed by the patient’s body before settling in the bone marrow.

Moreover, due to the growing focus of stem cell-based research and the rising demand for novel treatments, several companies, such as Stemline Therapeutics, have been focusing on developing technologies and treatments to attack cancer cells, which may help the market grow. However, owing to the COVID-19 pandemic, the detection and treatment of new cancer cases are impended, which may slightly impact the segment growth in the year.

Stem Cell Market Share

To understand key trends, Download Sample Report

North America Captured The Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall stem cell market, with the United States contributing to the largest share in the market. The United States and Canada have developed and well-structured healthcare systems. These systems also encourage research and development. The increasing number of cancer cases is providing opportunities for market players. The major market players are focusing on R&D activities to introduce new stem cell therapies in the market.

For instance, the National Cancer Institute (NCI) had stated that the national expenditure on cancer care was expected to reach USD 156 billion by 2020. This factor is expected to boost the growth of the market in the future. In December 2019, the researchers at the National Eye Institute (NEI) launched a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD), a leading cause of vision loss among people aged 65 years and above.

In addition, the current situation of COVID-19 is another factor driving the growth of the market in the country, as research activities are undergoing for the treatment of COVID-19. Stem cell therapy can also be a promising approach for the treatment of COVID-19 in the future. For instance, on May 6, 2020, Lineage Cell Therapeutics received a grant of USD 5 million from the California Institute for Regenerative Medicine (CIRM) to support the use of VAC, Lineage’s allogeneic dendritic cell therapy for the development of a potential vaccine against SARS-CoV-2, the virus that causes COVID-19.

Stem Cell Market Geography Trends

To understand geography trends, Download Sample Report

Competitive Landscape

The stem cell market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Thermo Fisher Scientific (Qiagen NV), Sigma Aldrich (a subsidiary of Merck KGaA), Becton, Dickinson and Company, and Stem Cell Technologies, is in turn, increasing the overall competitive rivalry in the market. The product advancements and improvement in stem cell technology by the major players are also increasing the competitive rivalry.

Recent Developments

In August 2020, Cipla and Stempeutics collaborated to launch Stempucel cell therapy to treat critical limb ischemia.

In March 2021, OrganaBio launched HematoPAC HSC-CB CD34 hematopoietic stem cell (HSC) product, which is helpful in supporting HSC-based allogeneic cell therapies.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increased Awareness about Umbilical Stem Cell

      2. 4.2.2 Rising R&D Initiatives to Develop Stem Cell Therapies and Increasing Approvals for Clinical Trials in Stem Cell Research

      3. 4.2.3 Growing Demand for Regenerative Treatment Options

    3. 4.3 Market Restraints

      1. 4.3.1 Expensive Procedures

      2. 4.3.2 Regulatory Complications

      3. 4.3.3 Ethical and Moral Framework

    4. 4.4 Industry Attractiveness- Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Adult Stem Cell

      2. 5.1.2 Human Embryonic Cell

      3. 5.1.3 Pluripotent Stem Cell

      4. 5.1.4 Other Product Types

    2. 5.2 By Application

      1. 5.2.1 Neurological Disorders

      2. 5.2.2 Orthopedic Treatments

      3. 5.2.3 Oncology Disorders

      4. 5.2.4 Injuries and Wounds

      5. 5.2.5 Cardiovascular Disorders

      6. 5.2.6 Other Applications

    3. 5.3 By Treatment Type

      1. 5.3.1 Allogeneic Stem Cell Therapy

      2. 5.3.2 Autologic Stem Cell Therapy

      3. 5.3.3 Syngeneic Stem Cell Therapy

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 United Kingdom

        2. 5.4.2.2 Germany

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Smith & Nephew PLC

      2. 6.1.2 Pluristem Therapeutics Inc.

      3. 6.1.3 Thermo Fisher Scientific

      4. 6.1.4 Qiagen NV

      5. 6.1.5 Merck KGaA (Sigma Aldrich)

      6. 6.1.6 Becton, Dickinson and Company

      7. 6.1.7 Stem Cell Technologies Inc.

      8. 6.1.8 AllCells LLC

      9. 6.1.9 Miltenyi Biotec

      10. 6.1.10 International Stem Cell Corporation

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Stem Cell Market market is studied from 2018 - 2026.

The Global Stem Cell Market is growing at a CAGR of 10.24% over the next 5 years.

The Global Stem Cell Market is valued at 14 Billion USD in 2018.

The Global Stem Cell Market is valued at 26 Billion USD in 2026.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Thermo Fisher Scientific, Becton, Dickinson and Company, Stemcell Technologies Inc., Merck KGaA (Sigma Aldrich), PLURISTEM THERAPEUTICS INC. are the major companies operating in Global Stem Cell Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!